BG62489B1 - Приложение на диметилбензофурани като 5-нт3 антагонисти - Google Patents

Приложение на диметилбензофурани като 5-нт3 антагонисти Download PDF

Info

Publication number
BG62489B1
BG62489B1 BG99593A BG9959395A BG62489B1 BG 62489 B1 BG62489 B1 BG 62489B1 BG 99593 A BG99593 A BG 99593A BG 9959395 A BG9959395 A BG 9959395A BG 62489 B1 BG62489 B1 BG 62489B1
Authority
BG
Bulgaria
Prior art keywords
formula
enantiomer
methoxy
amino
cis
Prior art date
Application number
BG99593A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG99593A (en
Inventor
Georges H. Van Daele
Jean-Paul R. Bosmans
Willy J. Van Laerhoven
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG99593A publication Critical patent/BG99593A/xx
Publication of BG62489B1 publication Critical patent/BG62489B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BG99593A 1992-11-20 1995-04-20 Приложение на диметилбензофурани като 5-нт3 антагонисти BG62489B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (2)

Publication Number Publication Date
BG99593A BG99593A (en) 1995-12-29
BG62489B1 true BG62489B1 (bg) 1999-12-30

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99593A BG62489B1 (bg) 1992-11-20 1995-04-20 Приложение на диметилбензофурани като 5-нт3 антагонисти

Country Status (31)

Country Link
US (2) US5674868A (sv)
EP (1) EP0669919B1 (sv)
JP (1) JP2830952B2 (sv)
KR (1) KR0166661B1 (sv)
AT (1) ATE176232T1 (sv)
AU (1) AU680640B2 (sv)
BG (1) BG62489B1 (sv)
BR (1) BR9307477A (sv)
CA (1) CA2149044C (sv)
CZ (1) CZ287262B6 (sv)
DE (1) DE69323322T2 (sv)
DK (1) DK0669919T3 (sv)
ES (1) ES2129615T3 (sv)
FI (1) FI952458A0 (sv)
GR (1) GR3029831T3 (sv)
HU (2) HUT72740A (sv)
IL (3) IL119273A0 (sv)
LV (1) LV10956B (sv)
MX (1) MX9307257A (sv)
NO (2) NO307690B1 (sv)
NZ (1) NZ257854A (sv)
OA (1) OA10158A (sv)
PL (1) PL176051B1 (sv)
RO (1) RO115160B1 (sv)
RU (1) RU2116072C1 (sv)
SG (1) SG47488A1 (sv)
SK (1) SK282378B6 (sv)
TW (1) TW294595B (sv)
UA (1) UA49792C2 (sv)
WO (1) WO1994012494A1 (sv)
ZA (1) ZA938676B (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US6235745B1 (en) * 1997-04-18 2001-05-22 Janssen Pharmaceutica N.V. Use of 5HT3, antagonists for promoting intestinal lavage
KR100358374B1 (ko) * 1997-07-11 2002-10-25 얀센 파마슈티카 엔.브이. 5-ｈｔ3 및 5-ｈｔ4 매개된 질환에 유용한(+)-노르시사프라이드
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2546002C (en) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005054201A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
NZ551840A (en) 2004-06-30 2009-07-31 Janssen Pharmaceutica Nv Substituted 2-alkyl quinzolinone derivatives as PARP inhibitors
CN1980674B (zh) 2004-06-30 2011-05-25 詹森药业有限公司 作为parp抑制剂的2,3-二氮杂萘衍生物
US8080557B2 (en) 2004-06-30 2011-12-20 Janssen Pharmaceutica, Nv Quinazolinedione derivatives as PARP inhibitors
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
WO2009118384A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
US5674868A (en) 1997-10-07
RU2116072C1 (ru) 1998-07-27
ES2129615T3 (es) 1999-06-16
KR0166661B1 (ko) 1999-01-15
AU5465994A (en) 1994-06-22
PL176051B1 (pl) 1999-03-31
UA49792C2 (uk) 2002-10-15
FI952458A (sv) 1995-05-19
BG99593A (en) 1995-12-29
IL119273A0 (en) 1996-12-05
HU9501476D0 (en) 1995-07-28
BR9307477A (pt) 1999-06-29
HU211546A9 (en) 1995-12-28
PL309045A1 (en) 1995-09-18
WO1994012494A1 (en) 1994-06-09
CA2149044C (en) 2007-04-03
HUT72740A (en) 1996-05-28
MX9307257A (es) 1994-05-31
NO308530B1 (no) 2000-09-25
CA2149044A1 (en) 1994-06-09
TW294595B (sv) 1997-01-01
IL107654A (en) 1998-01-04
CZ287262B6 (en) 2000-10-11
LV10956B (en) 1996-10-20
OA10158A (en) 1996-12-18
RU95113434A (ru) 1997-03-10
GR3029831T3 (en) 1999-06-30
IL107654A0 (en) 1994-02-27
RO115160B1 (ro) 1999-11-30
AU680640B2 (en) 1997-08-07
SK67595A3 (en) 1995-11-08
JPH08505840A (ja) 1996-06-25
US5863923A (en) 1999-01-26
SG47488A1 (en) 1998-04-17
LV10956A (lv) 1995-12-20
NO995762L (no) 1995-05-19
ZA938676B (en) 1995-05-19
JP2830952B2 (ja) 1998-12-02
NO995762D0 (no) 1999-11-24
FI952458A0 (sv) 1995-05-19
DE69323322T2 (de) 1999-09-09
NZ257854A (en) 1997-04-24
DK0669919T3 (da) 1999-09-13
CZ125895A3 (en) 1995-10-18
EP0669919B1 (en) 1999-01-27
EP0669919A1 (en) 1995-09-06
NO951980D0 (no) 1995-05-19
NO307690B1 (no) 2000-05-15
SK282378B6 (sk) 2002-01-07
IL119273A (en) 2000-07-16
DE69323322D1 (de) 1999-03-11
NO951980L (no) 1995-05-19
ATE176232T1 (de) 1999-02-15

Similar Documents

Publication Publication Date Title
JP3940359B2 (ja) 化合物
US7189713B2 (en) Piperidine derivatives
EP1339406B1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
BG62489B1 (bg) Приложение на диметилбензофурани като 5-нт3 антагонисти
AU2001295723A1 (en) Chemical compounds
DE60127434T2 (de) Benzoxazinonderivative, deren herstellung und verwendung
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
WO1992022527A2 (en) 3-substituted pyrrolidine derivatives as calcium channel antagonists
US20110230485A1 (en) 6-phenyl-pyrimidin-4-yl-(phenylamine or phenoxy) derivatives useful as modulators of nicotinic acetylcholine receptors
EP2393800B1 (en) Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
JP2001512491A (ja) １−（イソキノリン−１−イル）−４−（１−フェニメチル）ピペラジン；ドーパミン受容体サブタイプ特異的リガンド
KR19980701921A (ko) 혈관 수축성 치환된 2,3-디하이드로-1,4-디옥시노피리딘
WO2007009758A2 (en) 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist